Recursion Pharmaceuticals ( RXRX 3.12%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

B y any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

But stablecoin's future might hinge on whether it becomes mainstream digital money for low-cost payments or a tool for a growing universe of risky leveraged finance. For widespread stablecoin adoption ...

For consumers, however, the incentives look weaker. Credit cards offer rich rewards programs, while deposits and money-market funds pay interest. By contrast, the GENIUS Act explicitly prohibits ...

After eight years of renovation and anticipation, the museum reopens this weekend with a two-day public celebration; ahead of the long-awaited debut, Observer got an exclusive preview.

Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, ...

Access to jobs is essential for economic growth. In Africa, unemployment rates are notably high. This paper reexamines the ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...